IGF-1 LR3 has not been studied as a therapeutic in controlled human trials. The points below describe mechanism-based risks drawn from animal studies and from the labeling of the approved IGF-1 drug — not a complete safety profile for this compound.
The short answer
The best-documented effect of IGF-1 LR3 in any species is not muscle growth. It is hypoglycemia, and specifically hypoglycemia that lasts. That is not an incidental finding — it is the direct consequence of the modification that defines the molecule. Removing IGF-binding-protein control leaves more free peptide acting for longer, and IGF-1 shares enough structural and functional overlap with insulin to lower blood glucose through insulin-receptor and IGF-1-receptor pathways alike.
Beyond glucose, the concerns are the general ones attached to sustained IGF-1 receptor activation, and the practical ones attached to unregulated material. There is no human safety dataset for this compound to weigh any of it against.
Hypoglycemia, and why duration is the problem
The quantitative picture comes from a study comparing native IGF-I with four binding-resistant variants including LR3IGF-I, in pigs and marmoset monkeys (PMID 9415072):
- The variants were consistently 2- to 3-fold more potent than IGF-I at lowering plasma glucose to its nadir, with potency tracking reduced IGFBP affinity.
- They suppressed glucose over a much longer period, producing roughly 4- to 8-fold greater cumulative hypoglycemia across four hours.
- Critically, the prolonged suppression was not simply proportional to the depth of the nadir. At doses matched for equal glucose-lowering depth, the variants still produced about twice the cumulative effect of IGF-I.
- Maximum glucose lowering reached 4.8 mmol/L in the pig — a large absolute drop.
That decoupling of depth from duration is the part most likely to be misjudged. A person calibrating by how they feel in the first hour would be reading the wrong variable: the analog's distinguishing hazard is the tail, not the peak. Hypoglycemia symptoms — shakiness, sweating, confusion, and in severe cases seizures or loss of consciousness — can therefore recur after an apparent recovery.
Anything else lowering glucose at the same time (insulin, sulfonylureas, extended fasting, endurance exercise) stacks onto that tail.
What the approved IGF-1 label warns about
Mecasermin (Increlex) is recombinant human IGF-1 with an FDA approval, and its labeling is the closest thing to a regulatory safety document for this class (Increlex label, DailyMed). Its precautions are instructive:
- Hypoglycemia — severe hypoglycemia leading to hypoglycemic seizures has been observed. The label requires administration shortly before or after (± 20 minutes) a meal or snack, and instructs that the dose be withheld entirely if the patient cannot eat.
- Hypersensitivity and anaphylaxis — systemic allergic reactions require interrupting treatment and seeking prompt medical attention.
- Intracranial hypertension — funduscopic examination is recommended at initiation and periodically thereafter.
- Lymphoid tissue hypertrophy — tonsillar and adenoidal enlargement requiring periodic examination.
- Slipped capital femoral epiphysis — any child developing a limp or hip/knee pain is evaluated for it.
- Contraindications — closed epiphyses and malignant neoplasia.
Every one of those attaches to the IGF-1 molecule that still responds to binding proteins. LR3 was engineered to remove that restraint, in people who are not fasting on a schedule and have no funduscopic exams booked.
Growth-signaling concerns
IGF-1 is a general proliferation and anti-apoptotic signal, and the epidemiology is not neutral. In UK Biobank analyses of 394,388 cancer-free participants, each 5 nmol/L higher serum IGF-I concentration was associated with increased risk of colorectal cancer (HR 1.08, 95% CI 1.03–1.13), breast cancer (HR 1.11, 1.07–1.15), prostate cancer (HR 1.08, 1.05–1.12), and thyroid cancer (HR 1.18, 1.01–1.37), with reduced risks of ovarian and liver cancer (PMID 32709735).
Two caveats belong with those numbers. They describe variation within the physiologic range of endogenous IGF-I, not exposure to a binding-resistant analog — the relationship cannot simply be extrapolated. And mean follow-up was 6.9 years, so reverse causality cannot be excluded. The honest reading is that sustained supraphysiologic IGF-1-receptor activation is a biologically live concern with no reassuring dataset behind it, not that a specific risk figure applies.
Product-quality risks
Practical risks apply to any compound obtained outside a regulated supply chain: injection-site redness, swelling, or irritation; non-specific symptoms such as headache and fatigue; and — more consequentially for a microgram-dosed peptide — no verified identity, purity, sterility, or concentration. A vial whose actual content differs from its label by a factor of two is a routine possibility, and for a compound whose main hazard is prolonged hypoglycemia, that uncertainty is not cosmetic. The dosing page covers why the arithmetic compounds this.
Sport & Anti-Doping Warning
IGF-1 LR3 is a long-acting insulin-like growth factor analogue noted by anti-doping experts as a potent, hard-to-detect performance enhancer; it is covered under the WADA category for peptide hormones and growth factors.
- >Overview of IGF-1 analogues and related substances under the WADA List
- >Educational article describing IGF-1 LR3 and its relevance to sport
Even without many public positive tests, laboratories treat IGF-1 LR3 as a high-priority target substance in the GH–IGF axis.